Recent developments include ending a licensing agreement with Teleost, partnering with AAVnerGene to advance gene therapy development, and presenting at a major biotech showcase.

• Greenland Mines Ltd ended its licensing agreement with Teleost as of April 1, 2026 [N1].
• The company partnered with AAVnerGene to accelerate cost-effective gene therapy development as of July 22, 2025 [N2].
• Greenland Mines presented at Biotech Showcase 2025 on innovative therapies for neurodegenerative diseases [N5].
• The company’s stock was noted among pre-market most active stocks on June 10, 2025 [N4].
• Discussions about company stock activity and developments were reported in June 2025 [N3].

Greenland Mines Ltd’s proprietary gene therapy platform targeting the Klotho protein addresses significant unmet medical needs in neurodegenerative diseases, supported by promising preclinical data showing cognitive improvement and neuroprotection. The company’s acquisition of approved generic oncology drugs and biosimilars provides a commercial foundation. The expansion into critical minerals mining could diversify revenue streams and strategic positioning. The development of specific assays for Klotho isoforms may enhance clinical development and diagnostic capabilities [S1][N2][N5].

The company operates in highly complex and competitive sectors with significant scientific, regulatory, and commercial risks. Its gene therapy candidates remain in pre-clinical stages with no current market approvals. The recent expansion into mining represents a strategic shift that may dilute focus and resources. The company reported a substantial net loss and has no disclosed revenue, indicating ongoing funding needs. The success of its therapies depends on future clinical validation and regulatory approvals, which are uncertain [S1][S2].

The company’s moat is based on its proprietary gene therapy platform targeting the Klotho protein, supported by issued and pending patents, and exclusive worldwide rights licensed from the Autonomous University of Barcelona. Its multi-faceted approach to neurodegenerative diseases, including Alzheimer’s and ALS, leverages unique gene therapy technology with demonstrated preclinical efficacy. Additionally, the acquisition of market-approved generic and biosimilar drugs provides a foundation in oncology therapeutics. The recent expansion into mining diversifies its asset base but is a new area without established competitive advantages [S1].

• Clinical and Regulatory Risk: Gene therapy candidates are in pre-clinical stages with uncertain clinical outcomes and regulatory approvals.
• Financial Risk: The company reported a net loss of $13.9 million for Q1 2026 and has no disclosed revenue, indicating reliance on external funding.
• Strategic Risk: Expansion into mining is a new business area that may divert focus and resources from core biopharmaceutical development.
• Market and Competitive Risk: The biotechnology and mining sectors are highly competitive with rapid technological changes and market dynamics.

• Greenland Mines Ltd, formerly Klotho Neurosciences, Inc., develops medicines for chronic diseases including cancer, cardiovascular, and neurodegenerative disorders as of 2026-03-31 [S1].
• The company acquired five market-approved anti-cancer drugs in Germany in 2022, including drugs used in FOLFOX and FOLFIRI regimens for metastatic colorectal, gastric, and lung cancers [S1].
• It also acquired off-patent bio generic antibodies from Reliance Life Sciences [S1].
• In March 2026, Greenland Mines Corp. was acquired, expanding operations into critical and precious minerals development and mining [S1].
• The company’s gene therapy platform focuses on a proprietary gene therapy approach to produce the therapeutic protein Klotho for neurodegenerative diseases, including Alzheimer’s disease and ALS [S1].
• The gene therapy candidates are in pre-clinical stages, with plans to seek market approval in multiple countries [S1].
• The Klotho protein, especially the secreted isoform s-KL, is studied for neuroprotective effects and potential treatment of cognitive decline and neurodegenerative diseases [S1].
• Preclinical studies in mice show that increasing s-KL levels via gene therapy improves cognition and may clear beta-amyloid plaques associated with Alzheimer’s disease [S1].
• Research also indicates s-KL may have therapeutic potential in ALS by preserving motor neurons and neuromuscular junctions, delaying disease progression in animal models [S1].
• The company is developing assays to measure Klotho isoforms to support gene therapy development and potential diagnostics [S1].
• Financial snapshot as of 2026-03-31 shows cash and equivalents of $10,002,477, current assets of $10,931,642, current liabilities of $553,739, resulting in a current ratio of 19.74 and cash ratio of 18.06 [S2].
• Net loss for the quarter ended 2026-03-31 was $13,857,203 with basic and diluted EPS of -$0.15 [S2].
• The company’s common stock and warrants trade on Nasdaq under symbols GRML and GRMLW [S1].
• Recent business news includes ending a licensing agreement with Teleost and partnering with AAVnerGene to accelerate gene therapy development [N1][N2].
• The company presented at Biotech Showcase 2025 on innovative therapies for neurodegenerative diseases [N5].